Form 4: 89bio Director Disposes Options in Roche Merger

89bio Director Steven Altschuler disposed of all his stock options as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

Summary

• Steven Altschuler, a Director of 89bio, Inc. (ETNB), reported the disposition of all his derivative securities (stock options) on October 30, 2025.
• The disposition occurred pursuant to the Agreement and Plan of Merger, dated September 17, 2025, between 89bio, Inc., Roche Holdings, Inc. ('Parent'), and Bluefin Merger Subsidiary, Inc. ('Merger Sub').
• On October 30, 2025, Parent and Merger Sub completed a tender offer for all outstanding shares of 89bio common stock.
• The offer price was $14.50 per share in cash (the 'Closing Amount') plus one non-tradeable contingent value right (CVR) representing the right to receive contingent payments of up to an aggregate of $6.00 per share upon achievement of specified milestones.
• Following the tender offer, Merger Sub merged with and into 89bio, Inc., with 89bio continuing as a wholly-owned subsidiary of Roche Holdings, Inc.
• Immediately prior to the merger's effective time, all outstanding stock options became fully vested and exercisable.
• Options not exercised prior to the merger were cancelled and converted into the right to receive cash equal to (Closing Amount exercise price) multiplied by the number of shares, plus one CVR per share.
• Options with an exercise price equal to or greater than the Closing Amount ($14.50) but less than $20.50 ('Out of the Money Options') were converted into the right to receive only CVRs initially, with potential future cash payments tied to milestone achievements.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment of the Closing Amount or CVR.
• Mr. Altschuler disposed of multiple tranches of stock options, totaling 213,450 shares, with exercise prices ranging from $2.64 to $24.29.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of an acquisition providing shareholders with a cash payment and potential upside via CVRs. The disposition of options is a procedural outcome of this positive corporate event, though some options were cancelled without value.

Positives

• The merger provides 89bio shareholders with immediate cash value of $14.50 per share.
• Shareholders also receive a Contingent Value Right (CVR) offering potential additional payments of up to $6.00 per share, providing upside potential based on future milestones.
• All outstanding stock options became fully vested and exercisable prior to the merger, allowing option holders to realize value.

Negatives

• 89bio, Inc. ceases to be an independent publicly traded company, becoming a wholly-owned subsidiary of Roche Holdings, Inc.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in no value for those specific option holders.
• The CVRs are non-tradeable and contingent on future milestones, meaning their full value is not guaranteed and cannot be immediately realized.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specified milestones on or prior to applicable outside dates.
• CVRs are non-tradeable, limiting liquidity and the ability for holders to sell their rights prior to milestone achievement.
• There is a risk that the full $6.00 per share from the CVRs may not be realized if milestones are not met.

Future Outlook

89bio, Inc. will operate as a wholly-owned subsidiary of Roche Holdings, Inc. following the completion of the merger. The future performance of the CVRs will depend on the achievement of specified milestones by 89bio's assets under Roche's ownership.

Industry Context

This acquisition reflects a continuing trend of consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and gain access to innovative therapies. Roche's acquisition of 89bio, Inc. is a strategic move to integrate 89bio's assets into its portfolio, potentially accelerating development and commercialization with Roche's extensive resources.

Corporate Governance

Stakeholder Impact

• Shareholders of 89bio, Inc. received $14.50 per share in cash and one non-tradeable CVR for up to an additional $6.00 per share, realizing value from their investment.
• Employees who held stock options were impacted by the vesting and conversion terms outlined in the merger agreement, with some options potentially cancelled without value depending on their exercise price.
• 89bio, Inc. as a corporate entity is now integrated into Roche Holdings, Inc., affecting its operational autonomy and strategic direction.

Next Steps

• 89bio, Inc. will continue operations as a wholly-owned subsidiary of Roche Holdings, Inc.
• Holders of Contingent Value Rights (CVRs) will await the achievement of specified milestones for potential additional payments.

Key Dates

Keywords

89bio, ETNB, Roche, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Contingent Value Right, CVR, Tender Offer